Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Main billing specialties: vascular surgery, interventional radiology and cardiology.
Medicare fee-for-service peripheral arterial intervention cases in the 50 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 147 | 24,119−1.9%/yr | −1.9%/yr | 6.91.3× | 85% | 23,300 in 2030−0.6%/yr |
| Florida | 132 | 20,074−3.1%/yr | −3.1%/yr | 8.51.6× | 70% | 23,800 in 2030+2.9%/yr |
| Texas | 128 | 16,813−7.6%/yr | −7.6%/yr | 7.41.4× | 58% | 19,600 in 2030+2.6%/yr |
| New York | 97 | 12,468−0.1%/yr | −0.1%/yr | 6.51.2× | 60% | 16,300 in 2030+4.6%/yr |
| New Jersey | 55 | 8,709+2.3%/yr | +2.3%/yr | 8.01.5× | 77% | 12,700 in 2030+6.4%/yr |
| Maryland | 52 | 6,992−4.8%/yr | −4.8%/yr | 7.71.4× | 84% | 8,070 in 2030+2.4%/yr |
| Illinois | 47 | 6,194−7.5%/yr | −7.5%/yr | 4.30.8× | 41% | 6,330 in 2030+0.4%/yr |
| Tennessee | 45 | 5,546−6.3%/yr | −6.3%/yr | 7.51.4× | 70% | 6,500 in 2030+2.7%/yr |
| Michigan | 34 | 4,986−13%/yr | −13%/yr | 5.61.0× | 65% | 5,540 in 2030+1.8%/yr |
| North Carolina | 34 | 4,853−8.1%/yr | −8.1%/yr | 4.60.9× | 39% | 4,620 in 2030−0.8%/yr |
| Arizona | 38 | 4,850−6.8%/yr | −6.8%/yr | 6.21.2× | 74% | 4,560 in 2030−1%/yr |
| Pennsylvania | 34 | 4,796−11%/yr | −11%/yr | 3.30.6× | 15% | 4,870 in 2030+0.3%/yr |
| Virginia | 30 | 3,751−7.6%/yr | −7.6%/yr | 3.50.6× | 43% | 5,530 in 2030+6.7%/yr |
| Ohio | 26 | 3,751−11%/yr | −11%/yr | 3.20.6× | 4% | 3,700 in 2030−0.2%/yr |
| Georgia | 21 | 3,651−12%/yr | −12%/yr | 4.00.8× | 46% | 4,960 in 2030+5.3%/yr |
| Massachusetts | 34 | 3,386−4.6%/yr | −4.6%/yr | 3.50.6× | 43% | 4,060 in 2030+3.1%/yr |
| Arkansas | 23 | 2,979−1.4%/yr | −1.4%/yr | 7.61.4× | 45% | 2,520 in 2030−2.8%/yr |
| Indiana | 18 | 2,941−9.6%/yr | −9.6%/yr | 4.00.7× | 16% | 2,980 in 2030+0.2%/yr |
| Missouri | 19 | 2,750−14%/yr | −14%/yr | 4.20.8× | 21% | 3,390 in 2030+3.5%/yr |
| Louisiana | 12 | 2,691−14%/yr | −14%/yr | 6.31.2× | 32% | 2,760 in 2030+0.4%/yr |
| South Carolina | 19 | 2,514−4.5%/yr | −4.5%/yr | 3.50.7× | 25% | 3,310 in 2030+4.7%/yr |
| Oklahoma | 19 | 2,386−5.2%/yr | −5.2%/yr | 4.70.9× | 47% | 3,400 in 2030+6.1%/yr |
| Mississippi | 27 | 2,361−7.9%/yr | −7.9%/yr | 6.11.1× | 73% | 2,320 in 2030−0.3%/yr |
| Alabama | 19 | 2,322−11%/yr | −11%/yr | 5.00.9× | 47% | 2,130 in 2030−1.4%/yr |
| Kentucky | 22 | 2,281−6.3%/yr | −6.3%/yr | 4.70.9× | 43% | 2,570 in 2030+2%/yr |
| Kansas | 13 | 2,258−6.3%/yr | −6.3%/yr | 5.41.0× | 53% | 2,010 in 2030−1.9%/yr |
| Washington | 15 | 2,037−9%/yr | −9%/yr | 2.50.5× | 14% | 2,490 in 2030+3.4%/yr |
| Wisconsin | 15 | 1,979−9.4%/yr | −9.4%/yr | 3.30.6× | 2% | 2,150 in 2030+1.4%/yr |
| Connecticut | 14 | 1,650−9%/yr | −9%/yr | 4.70.9× | 71% | 1,560 in 2030−1%/yr |
| Minnesota | 9 | 1,536−8.4%/yr | −8.4%/yr | 3.20.6× | 0% | 2,960 in 2030+12%/yr |
| South Dakota | 13 | 1,501−0.4%/yr | −0.4%/yr | 11.22.1× | 76% | 1,800 in 2030+3%/yr |
| Oregon | 14 | 1,434−4.5%/yr | −4.5%/yr | 3.30.6× | 63% | 1,890 in 2030+4.7%/yr |
| District of Columbia | 10 | 1,226+9.5%/yr | +9.5%/yr | 18.93.5× | 83% | 1,830 in 2030+6.9%/yr |
| Nevada | 9 | 1,215−6.2%/yr | −6.2%/yr | 4.00.8× | 73% | 1,790 in 2030+6.7%/yr |
| Nebraska | 9 | 1,170−1.7%/yr | −1.7%/yr | 4.40.8× | 62% | 2,150 in 2030+11%/yr |
| Iowa | 8 | 1,121−12%/yr | −12%/yr | 2.40.5× | 11% | 1,490 in 2030+4.9%/yr |
| Colorado | 6 | 1,107−8.7%/yr | −8.7%/yr | 2.20.4× | 43% | 1,830 in 2030+8.7%/yr |
| Delaware | 8 | 910−1%/yr | −1%/yr | 5.21.0× | 79% | 2,020 in 2030+14%/yr |
| Utah | 6 | 843+4%/yr | +4%/yr | 3.70.7× | 48% | 190 in 2030−22%/yr |
| West Virginia | 5 | 769−11%/yr | −11%/yr | 3.50.7× | 0% | 840 in 2030+1.4%/yr |
| Idaho | 5 | 646+5.1%/yr | +5.1%/yr | 3.00.6× | 47% | 4,230 in 2030+37%/yr |
| New Mexico | 3 | 559−14%/yr | −14%/yr | 2.30.4× | 9% | 460 in 2030−3.1%/yr |
| New Hampshire | 5 | 534−11%/yr | −11%/yr | 2.30.4× | 0% | 1,240 in 2030+15%/yr |
| Hawaii | 2 | 363+2.9%/yr | +2.9%/yr | 2.70.5× | 91% | 690 in 2030+11%/yr |
| North Dakota | 5 | 361−11%/yr | −11%/yr | 3.50.7× | 0% | 220 in 2030−8.1%/yr |
| Rhode Island | 4 | 346−12%/yr | −12%/yr | 3.60.7× | 54% | 380 in 2030+1.5%/yr |
| Montana | 5 | 334−8.2%/yr | −8.2%/yr | 1.70.3× | 0% | 370 in 2030+1.5%/yr |
| Maine | 1 | 250−14%/yr | −14%/yr | 1.50.3× | 0% | 260 in 2030+0.5%/yr |
| Alaska | 4 | 237+4%/yr | +4%/yr | 2.00.4× | 0% | 380 in 2030+8.3%/yr |
| Wyoming | 1 | 176+0.3%/yr | +0.3%/yr | 1.60.3× | 0% | 200 in 2030+2%/yr |
Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 670 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 42 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Boston Scientific | 142 |
| Medtronic | 109 |
| W L Gore & Associates | 97 |
| BD | 53 |
| Biotronik | 52 |
| Cordis | 49 |
| Abbott | 37 |
| Terumo | 27 |
| Veryan Medical | 15 |
| Cook | 13 |
| Eximo Medical | 8 |
| Cardiovascular Systems | 7 |
Product codes: LIT (catheter, angioplasty, peripheral, transluminal), MCW (catheter, peripheral, atherectomy), NIO (stent, iliac), NIP (stent, superficial femoral artery), PRC (drug-coated peripheral transluminal angioplasty catheter). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +10 pts since 2019, to 61%.
The 10 busiest do 32% of the cases CMS names in California; 59 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Superficial venous ablation | 1,980 | 166,794−4.1%/yr | −4.1%/yr | 191,600 in 2030+2.3%/yr |
| Dialysis access | 1,721 | 161,268−13%/yr | −13%/yr | 158,700 in 2030−0.3%/yr |
| Thrombectomy, IVC filters & venous stents | 389 | 47,332+0.1%/yr | +0.1%/yr | 62,700 in 2030+4.8%/yr |
| Carotid revascularization | 741 | 36,694−5%/yr | −5%/yr | 40,000 in 2030+1.5%/yr |
| Aortic endografts (EVAR/TEVAR) | 89 | 13,204−6.8%/yr | −6.8%/yr | 13,800 in 2030+0.7%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 15 companies reported engagement with surgeons in the covered states worth $2.7M in consulting, speaking, meals and travel tied to these products, about $2,014 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.